艾拉司群(Elacestrant hydrochloride) - 药物靶点：ERα_在研适应症：晚期乳腺癌，转移性乳腺癌，ER阳性/HER2阴性/ESR1突变乳腺癌_专利_临床

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

开始日期2026-06-01

申办/合作机构-

NCT07612215

/ Recruiting临床1/2期IIT

Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)

The purpose of this study to assess the safety and efficacy of elacestrant, a selective estrogen receptor degrader (SERD) and dual biologic therapy, trastuzumab and pertuzumab, in patients with triple-positive breast cancer with and without an ESR1 mutation.

开始日期2026-05-13

申办/合作机构

NYU Langone Health

NCT07395336

/ Recruiting临床2期IIT

Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE): a Proof-of-concept Phase 2 Clinical Trial

Single agent endocrine therapy (ET), with selective estrogen receptor degraders (SERDs; i.e. fulvestrant or elacestrant), is an option for patients with pre-treated hormone receptor-positive (HR+) breast cancer (BC) with indolent behaviour beyond the first line therapy with CDK4/6 inhibitors (CDK4/6i) + ET, in order to spare the adverse events related to chemotherapy.
Anyway, the efficacy of endocrine monotherapy in patients progressing on first line therapy is low, because of the occurrence of endocrine resistance mechanisms, like the HR loss and the switch to HR-negative subtype, caused by the selective pressure of first line therapy; furthermore, biomarkers for patient selection are missing.
Recently, the 16a-[18F]fluoro-17b-estradiol positron emission tomography ([18F]FES-PET) demonstrated a sensitivity and specificity of 86% in estrogen receptor expression prediction; therefore it is a promising tool to select patients progressing on CDK4/6i + ET without HR loss.
Single agent endocrine therapy (ET), with selective estrogen receptor degraders (SERDs; i.e. fulvestrant or elacestrant), is an option for patients with pre-treated hormone receptor-positive (HR+) breast cancer (BC) with indolent behaviour beyond the first line therapy with target cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) + ET, in order to spare the adverse events related to chemotherapy.
Anyway, the efficacy of endocrine monotherapy in patients progressing on first line therapy is low, because of the occurrence of endocrine resistance mechanisms, like the Hormon Receptor (HR) loss and the switch to HR-negative subtype, caused by the selective pressure of first line therapy; furthermore, biomarkers for patient selection are missing.
Recently, the 16a-[18F] fluoro-17b-estradiol positron emission tomography ([18F] FES-PET) demonstrated a sensitivity and specificity of 86% in estrogen receptor expression prediction; therefore it is a promising tool to select patients progressing on CDK4/6i + ET without HR loss.
The combination of endocrine agent, namely fulvestrant 250 mg plus anastrozole 1 mg (an aromatase inhibitor), demonstrated to provide an overall survival benefit in patients with Hormon Receptor positive Breast Cancer only in first line setting but not in patients progressing to ET. However, meanwhile, fulvestrant 500 mg was demonstrated to be superior to fulvestrant 250 mg in 2nd line setting, and oral SERDs (e.g. Elacestrant, Camizestrant) were demonstrated to be superior in terms of Progression Free Survival to fulvestrant 500 mg in patients progressing on ET, in the subgroup of patients with estrogen receptor 1 gene (ESR1) mutations.
Hypothesis: there is a strong rationale to assess the safety and the activity of Elacestrant plus exemestane in patients with pre-treated HR+ and Human Epidermal Growth Factor Receptor 2 negative (HER2-) metastatic breast cancer and at least 50% of [18F]FES-avid measurable lesions, using [18F]FES PET/CT to evaluate the early response to treatment.

开始日期2026-05-11

申办/合作机构

Istituto Europeo di Oncologia Srl

100 项与艾拉司群相关的临床结果

登录后查看更多信息

100 项与艾拉司群相关的转化医学

登录后查看更多信息

100 项与艾拉司群相关的专利（医药）

登录后查看更多信息

109

项与艾拉司群相关的文献（医药）

2026-06-03·Expert Review of Anticancer Therapy

Elacestrant in metastatic breast cancer: current advancements and future perspectives

Review

作者: Aksoy, Sercan ; Sahin, Taha Koray ; Rizzo, Alessandro ; Guven, Deniz Can ; Di Lauro, Vincenzo ; Makasheva, Binura

INTRODUCTION:

Hormone receptor-positive and HER2-negative advanced breast cancer is the most prevalent subtype and poses therapeutic challenges. While endocrine therapy remains the cornerstone of management, acquired resistance, particularly stemming from ESR1 mutations, limits long-term efficacy. Consequently, novel endocrine agents with enhanced potency, oral bioavailability, and favorable tolerability are crucial for overcoming resistance and improving patient outcomes.

AREAS COVERED:

This review provides a comprehensive evaluation of elacestrant, an orally active selective estrogen receptor degrader that has transformed the treatment paradigm for endocrine resistant disease. The pharmacologic properties, antitumor activity, and clinical outcomes associated with elacestrant are discussed in detail, along with ongoing research exploring its integration into combination regimens and in earlier disease settings.

EXPERT OPINION:

Elacestrant has become an important therapeutic option for patients with ESR1-mutated disease, offering durable estrogen receptor suppression and favorable tolerability. Combination therapies targeting CDK4/6 and PI3K-AKT-TOR signaling pathways represent promising directions for extending endocrine sensitivity. With the growing integration of liquid biopsy technologies and molecular monitoring into clinical practice, dynamic treatment adaptation guided by real time molecular profiling is expected to refine therapy selection. Elacestrant is a benchmark in the shift toward individualized endocrine therapy in metastatic breast cancer, bridging molecular precision with clinical practicality.

2026-04-01·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis

Review

作者: Oggionni, Emanuela ; Balconi, Elena ; Parati, Maria Chiara ; Rossitto, Mauro ; Petrò, Daniela ; Petrelli, Fausto ; Ghilardi, Mara ; Colombo Zefinetti, Lara ; Dottorini, Lorenzo ; Borgonovo, Karen ; Zambelli, Alberto ; Dognini, Giuseppina ; Castelli, Emanuela

IMPORTANCE:

Randomized controlled trials (RCTs) establish the efficacy of new oncology drugs but often exclude older adults, patients with comorbidities, and individuals with poorer performance status. Real-world evidence (RWE) is therefore essential to determine whether trial benefits translate to the broader populations treated in routine practice.

OBJECTIVE:

To synthesize contemporary RWE on the effectiveness and safety of ten oncology drugs approved between 2020 and 2025 for solid tumors, focusing on studies with ≥ 100 patients to maximize robustness and generalizability.

EVIDENCE REVIEW:

A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and major conference proceedings (ASCO, ESMO, AACR) identified observational cohorts, registries, expanded-access programs, and claims-based studies published from January 2020 to January 2025.

FINDINGS:

Twenty studies (N > 3400) met inclusion criteria: breast cancer (9), lung cancer (7), urothelial carcinoma (3), and endometrial cancer (1). In breast cancer, sacituzumab govitecan reproduced ASCENT outcomes (ORR 27-30 %; PFS 4.8-5.2 months), trastuzumab deruxtecan achieved ORRs near 70 % in HER2-positive disease and median PFS 7.5 months in HER2-low cohorts, and elacestrant showed real-world time-to-next-treatment of 7.9-10.8 months in ESR1-mutant ER+ /HER2 - disease. In NSCLC, sotorasib and adagrasib demonstrated ORRs of ∼28-34 % and PFS 3.5-6 months, selpercatinib provided durable disease control, and MET inhibitors (capmatinib, tepotinib) yielded PFS around 6-7 months. In urothelial carcinoma, enfortumab vedotin produced ORRs of 31-73 % across datasets. In endometrial cancer, dostarlimab generated highly durable responses in dMMR/MSI-H disease.

CONCLUSIONS:

RWE confirms the effectiveness and safety of multiple recently approved oncology drugs reinforcing the external validity of RCTs.

2026-03-01·BIOMEDICAL CHROMATOGRAPHY

Characterization of In Vitro Metabolic Profiles of Elacestrant in Rat and Human Liver Microsomes Using HPLC–MS/MS and HPLC–Q‐Orbitrap–HRMS

Article

作者: Chen, Yonggang ; Wang, Fang ; Liu, Wenxia ; Hu, Min ; Chen, Shangxiu

ABSTRACT:

Elacestrant is an orally administered selective estrogen receptor degrader designed for the treatment of ER‐positive, HER2‐negative breast cancer. In this study, a simple and sensitive HPLC–MS/MS method was developed and validated for the quantification of elacestrant in liver microsomes. Chromatographic separation was achieved on a Waters ACQUITY BEH C 18 column using a gradient of 0.1% formic acid in water and acetonitrile. Elacestrant and the internal standard (elacestrant‐d 6 ) were detected in multiple reaction monitoring mode via the transitions of m/z 459.2 → 298.3 and m/z 465.3 → 304.4, respectively. The method exhibited excellent linearity over the range of 1.0–2000 nM ( r > 0.995). Elacestrant was rapidly metabolized, showing half‐lives of 22.45 ± 0.66 min in rat liver microsomes and 43.36 ± 2.48 min in human liver microsomes. Using HPLC–Q‐Orbitrap–HRMS, seven metabolites were identified, with M5 ( N ‐deethylation) being the most abundant. Key metabolic pathways involved O ‐demethylation, N ‐deethylation, N ‐dealkylation, and oxidative deamination, primarily mediated by cytochrome P450 3A4. This study establishes the first HPLC–MS/MS and HPLC–Q‐Orbitrap–HRMS–based analytical strategy for in vitro metabolic profiling of elacestrant, supporting its future application in clinical pharmacokinetic and metabolism investigations.

373

项与艾拉司群相关的新闻（医药）

2026-06-03

·allsci.com

FDA accepts Roche’s giredestrant NDA for early-stage ER-positive breast cancer adjuvant treatment

Roche (SIX: RO, ROP; OTCQX: RHHBY) has submitted a New Drug Application (NDA) to the US FDA for giredestrant, an investigational oral selective estrogen receptor degrader (SERD), as adjuvant treatment for adults with estrogen receptor (ER)-positive, HER2-negative stage I, II, and III breast cancer. The FDA has accepted the filing under Priority Review, marking a significant regulatory milestone for an oral SERD in the adjuvant breast cancer setting. The NDA, submitted under Priority Review, seeks approval for giredestrant as an adjuvant endocrine therapy in patients with ER-positive, HER2-negative early-stage breast cancer across stage I through III. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of 30 November 2026, the company said. Separately, Roche noted that the FDA has also accepted an NDA for giredestrant in combination with everolimus for ESR1-mutated ER-positive advanced breast cancer, with a decision expected in December 2026. The filing is supported by data from the lidERA Breast Cancer study (NCT04961996), a Phase III, randomized, open-label, multicenter trial evaluating adjuvant giredestrant versus standard-of-care endocrine therapy in patients with medium- or high-risk stage I–III ER-positive, HER2-negative breast cancer. The trial enrolled more than 4,100 patients, with invasive disease-free survival (iDFS) as the primary endpoint. Results demonstrated that giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy (hazard ratio 0.70; 95% confidence interval 0.57–0.87; p\=0.0014). At three years, 92.4% of patients in the giredestrant arm were alive and free of invasive disease, compared with 89.6% in the standard-of-care arm. The iDFS benefit was reported as consistent across clinically relevant subgroups. Overall survival data were immature at the time of analysis, though a positive directional trend was observed. The treatment discontinuation rate was 5.3% with giredestrant versus 8.2% with standard-of-care endocrine therapy, suggesting a tolerability profile that may support adherence. Giredestrant is an oral, potent next-generation SERD and full estrogen receptor antagonist designed to block estrogen binding and trigger receptor degradation, thereby inhibiting tumor cell proliferation. The adjuvant ER-positive breast cancer treatment landscape has long been anchored by tamoxifen and aromatase inhibitors, with no new endocrine therapy class introduced in over two decades. The only approved oral SERD currently on the market is Menarini/Radius Health’s elacestrant (Orserdu), which holds an indication in the metastatic setting for ESR1-mutated disease rather than the early-stage curative context. Fulvestrant, an injectable SERD, is used in advanced disease but lacks an adjuvant indication. Giredestrant’s Phase III data in the adjuvant setting therefore positions it in largely uncontested regulatory territory among oral SERDs, though the broader selective estrogen receptor degrader breast cancer field continues to attract development activity. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

2026-06-01

·PRNewswire

A combined therapeutic strategy aims to improve disease control in advanced hormone‑sensitive prostate cancer

MEDSIR has presented at the ASCO scientific congress, held in Chicago, the final results of its ZZ‑FIRST study, which support the potential of combining enzalutamide and talazoparib in high‑volume metastatic hormone‑sensitive prostate cancer. The study, which enrolled 54 patients from Spanish centers, evaluates a strategy to intensify standard therapy with the aim of blocking tumor progression before the cancer develops resistance to treatment, a frequent phenomenon in prostate cancer. CHICAGO, June 1, 2026 /PRNewswire/ -- MEDSIR, a leading international oncology research company, has presented the final results of the ZZ‑FIRST study during an oral session at the ASCO 2026 scientific congress, held in Chicago. This study evaluates a therapeutic intensification strategy in patients with advanced prostate cancer. Previously, the study demonstrated relevant treatment response results in more than 70% of cases, reflected by a decrease in PSA (prostate‑specific antigen) levels, a biomarker used in the blood monitoring of prostate cancer. ZZ-FIRST: a new therapeutic strategy Continue Reading Dr. Joaquin Mateo during ZZ-First oral session at ASCO 2026 In the ZZ‑FIRST study, a phase II, multicenter, randomized trial, 54 patients from eight centers across Spain were enrolled. Specifically, the trial included patients with high‑volume metastatic hormone‑sensitive prostate cancer (mHSPC), meaning a high tumor burden at diagnosis and typically a poorer prognosis. For these patients, current treatment is based on androgen deprivation therapy, usually in combination with next‑generation hormonal treatments such as enzalutamide. Since many prostate cancer cells depend on male hormones for growth (androgens such as testosterone), these therapies aim to block these hormonal signals by reducing testosterone levels and inhibiting their downstream effectors. However, over time, some tumors develop resistance and continue to grow despite hormonal blockade, becoming hormone‑resistant. In this context, the ZZ‑FIRST study evaluates the feasibility of intensifying initial treatment with enzalutamide by combining it with talazoparib (a PARP inhibitor, a protein involved in DNA repair) from earlier stages of the disease. By administering both drugs together while the disease is still hormone‑sensitive, the goal is to increase the accumulated DNA damage in tumor cells and promote their destruction before mechanisms of resistance to hormonal therapy emerge. The results presented at ASCO show that patients treated with the experimental combination achieved a radiographic progression‑free survival of 45.3 months, compared with 31.1 months in those treated with enzalutamide alone. This endpoint measures the time from treatment initiation until tumor progression is detected by imaging tests. In addition, patients receiving the combination also showed a longer time to PSA progression and to the development of resistance to hormonal therapy. In addition, adaptive tumor mechanisms were investigated before initiating therapy and during the first weeks of treatment with enzalutamide, providing key information to better understand how resistance develops. The ZZ‑FIRST results indicate that the combination of hormonal therapy with PARP inhibitors may particularly benefit patients whose tumors present certain mutation profiles in DNA repair genes. "Although patients with metastatic disease initially respond to hormonal therapy, the tumor eventually adapts and grows again. Therefore, it is essential to investigate the biological mechanisms that allow the tumor to develop resistance to hormonal treatment and to identify new therapeutic strategies capable of delaying or preventing this process," explained Dr. Joaquín Mateo, principal investigator of the study, oncologist at Vall d'Hebron University Hospital and Head of the Prostate Cancer Group at the Vall d'Hebron Institute of Oncology (VHIO), who presented the results at ASCO. ZZ‑FIRST has received external funding from Pfizer S.L., the Spanish Association Against Cancer (AECC), and the United States Department of Defense (DoD). The drugs used in the study were provided by Pfizer S.L. (talazoparib) and Astellas Pharma Europe Ltd. (enzalutamide). ADELA and CADILLAC: MEDSIR presence at the ASCO congress In addition to the presentation of the ZZ‑FIRST study, MEDSIR also presented the design of other studies during the congress. On the one hand, the company presented, in collaboration with the Menarini Group, the design of the ADELA study, an international phase III trial evaluating the selective estrogen receptor degrader (SERD) elacestrant combined with everolimus versus elacestrant monotherapy. The study includes patients with ER+/HER2‑ tumors who developed an ESR1 gene mutation after progression on prior endocrine therapy and CDK4/6 inhibitors. The trial is being implemented in more than 100 hospitals across nine countries, including Spain, Austria, the Czech Republic, Greece, the United Kingdom, France, Italy, Germany, and Brazil. On the other hand, the CADILLAC study is also noteworthy. This is an international phase II trial evaluating the efficacy and safety of combining the SERD camizestrant with the CDK4/6 inhibitor ribociclib in patients with advanced HR+/HER2‑ breast cancer who have stopped responding to standard treatments. The study, currently ongoing at centers in Spain, Germany, and China, includes 150 patients whose data will be compared with historical records from more than 150 patients receiving conventional therapy. About MEDSIR Founded in 2012, MEDSIR is distinguished by its close collaboration with strategic partners to drive innovation in oncology research. With headquarters in Spain and the United States, the company provides comprehensive management of clinical trials, from study design through to publication, supported by an extensive global network of experts and integrated technology to streamline the process. The company offers support for proof‑of‑concept studies and a strategic approach that allows research partners to benefit from the best of both worlds: industry clinical research and investigator‑driven trials. More information: SOURCE MEDSIR 21% more press release views with Request a Demo

临床结果临床2期临床3期

2026-05-30

·YAO资源

5月31日医药新闻

2026年5月31日国内外医药新闻速报国内要闻 1. 世界无烟日专题：今日是第39个世界无烟日，中国控烟与健康协会副秘书长杨杰表示，全国已有25个省及270多个城市制定控烟立法，国家层面控烟立法时机已经成熟。目前我国15岁以上人群吸烟率目标为2030年降至20%。 2. 创新药板块爆发：2026年创新药行业迎来五年拐点，政策从"控费"转向"护航"——生物医药首次列为国家新兴支柱产业，创新药审批提速、定价松绑、医保纳入周期从5年缩短至1年。2026年一季度科创板创新药企首次实现整体盈利。 3. ASCO年会中国成果：2026美国临床肿瘤学会年会正在芝加哥举行，中国药企6项核心LBA突破性研究亮相： - 迪哲医药舒沃替尼成为全球首个EGFR 20ins肺癌一线治疗阳性III期研究 - 康方生物依沃西单抗将于6月2日全体大会公布肺癌一线III期数据（年度最高级别中国成果） - 百利天恒、康宁杰瑞、恒瑞医药、科伦博泰均有核心数据公布 4. 新药研发进展：健康元药业1类新药注射用JKN2501获临床批件，为国内首个与美罗培南协同设计的广谱β-内酰胺酶抑制剂，针对重症耐药菌感染；华东医药三靶点激动剂DR10624获IND受理。国际要闻 1. 埃博拉疫情升级：WHO宣布刚果（金）和乌干达埃博拉疫情为国际关注突发公共卫生事件，截至5月25日已致230人死亡、900余例疑似病例。本次为罕见Bundibugyo毒株，暂无获批疫苗和特效药，疫情扩散速度超过防控能力。美国已启动入境限制与机场筛查。 2. GLP-1医保控费：美国CMS启动BALANCE模式，2027年1月起Medicare参保人使用GLP-1类减肥药/糖尿病药，月付上限将设为50美元，旨在控制医保支出快速增长。 3. 礼来代谢管线进展：礼来将于6月ADA大会公布核心数据：口服GLP-1药物Foundayo（orforglipron）III期结果显示疗效优于口服司美格鲁肽和达格列净，且服用无需饮食限制；首创三重激动剂retatrutide将公布肥胖与糖尿病并发症最新数据。 4. 乳腺癌治疗突破：Menarini公布Elacestrant联合Capivasertib治疗ER+/HER2-转移性乳腺癌1b/2期数据，联合方案可有效克服ESR1和PIK3CA突变耐药机制。

100 项与艾拉司群相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11671	艾拉司群	-	DB06374

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
晚期乳腺癌	英国	Stemline Therapeutics, Inc.	2024-01-05
转移性乳腺癌	英国	Stemline Therapeutics, Inc.	2024-01-05
ER阳性/HER2阴性/ESR1突变乳腺癌	美国	Stemline Therapeutics, Inc.	2023-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	申请上市	美国	Radius Pharmaceuticals, Inc.	2022-06-22
HR阳性/HER2阴性乳腺癌	临床3期	德国	Berlin-Chemie/Menarini Pharma GmbH	2026-04-29
ER阳性乳腺癌	临床3期	美国	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	阿根廷	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	澳大利亚	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	奥地利	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	比利时	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	巴西	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	加拿大	Stemline Therapeutics, Inc.	2024-09-27
ER阳性乳腺癌	临床3期	捷克	Stemline Therapeutics, Inc.	2024-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06492616 (ELEGANT, ASCO2026 \| AACR2026)	临床3期	ER阳性/HER2阴性乳腺癌 ESR1m	4,220	Elacestrant	淵範繭網糧廠顧繭獵廠(網鏇鹽蓋鏇餘廠鏇選壓) = 艱網願廠簾淵積齋鹽餘顧醖窪廠廠鹽艱顧鑰醖 (壓壓壓艱網壓鬱蓋憲壓 ) 更多	积极	2026-05-29
NCT06382948 (ADELA, ASCO2026 \| AACR2026)	临床3期	ER阳性/HER2阴性/ESR1突变乳腺癌 ESR1-mutated	240	Elacestrant + Everolimus	觸觸膚願願鬱鹽選鹽蓋(壓鹹鹹積鹹襯積窪遞願) = There was one case (0.5%) of Grade 5 AEs (interruption of CDK4/6i due to increased creatine phosphokinase) with Elacestrant + Everolimus and one case (0.5%) (gastrointestinal bleeding) with Elacestrant + Placebo. 衊鹹齋膚憲繭鏇窪構壓 (獵遞齋繭網範簾鹹顧範 ) 更多	积极	2026-05-29
NCT07222215 (CAPELA, ASCO2026)	临床2期	ER阳性乳腺癌 ER positive \| HER2 negative	297	Capecitabine + Elacestrant	醖餘願鬱繭遞鏇壓鏇鹽(鬱獵糧壓齋齋鑰淵壓廠) = 糧築齋網艱選鹽願窪襯衊衊膚選膚簾蓋鹹簾繭 (蓋獵衊鹹遞壓鏇淵餘遞 )	积极	2026-05-29
				Capecitabine	夢醖鹹夢觸範積夢膚艱(襯範範壓鑰繭壓蓋觸夢) = 淵簾選夢鏇艱遞鑰膚齋鹽衊膚簾鬱壓夢壓廠鏇 (積衊蓋蓋醖鹹願積簾壓 ) 更多
NCT05563220 (ELEVATE, ASCO2026)	临床1/2期	ER阳性/HER2阴性乳腺癌二线 \| 一线 ER+/HER2−	31	CapivasertibElacestrant + CapivasertibElacestrantb	廠獵窪糧蓋襯築壓憲淵(憲鏇襯鏇繭艱淵築襯鹽) = 鑰窪醖窪衊夢淵繭襯築遞鏇蓋範淵範築鏇鏇願 (獵願衊築積鹽鏇繭顧選 ) 更多	积极	2026-05-29
AACR2026	临床2/3期	HR阳性/HER2阴性乳腺癌 HR Positive \| HER2 Negative	16	Imlunestrant alone	蓋壓廠憲鏇鏇鬱蓋衊壓(醖構鬱醖憲積鑰積餘繭) = 艱繭夢築艱簾襯範網憲構遞願襯憲製範範窪鑰 (夢觸鹹壓壓憲繭鑰鹹夢 ) 更多	积极	2026-04-21
				Camizestrant 75mg	蓋壓廠憲鏇鏇鬱蓋衊壓(膚淵構鹹範齋簾窪觸壓) = 獵蓋積製艱簾窪鬱壓顧齋醖壓淵簾選糧壓簾顧 (齋獵鹽壓衊遞構鏇艱網 ) 更多
NCT06492616 (ELEGANT, SABCS2025)	临床3期	ER阳性/HER2阴性乳腺癌 ESR1-mut \| ER+ \| HER2-	4,220	Elacestrant	蓋襯顧淵構遞積醖窪遞(鬱廠繭淵網鹹願壓築鬱) = 夢鬱鹽觸鹹網糧壓顧鏇觸選壓選願顧鬱蓋齋蓋 (糧艱鏇積糧築鑰選鏇淵 )	积极	2025-12-11
NCT06382948 (ADELA, SABCS2025)	临床3期	ESR1-mutated \| ER+/HER2-	240	Elacestrant + Everolimus	襯衊襯齋衊願餘齋窪顧(遞觸顧積襯醖鹹餘糧選) = 選醖鹹齋艱廠網獵網鹽獵遞夢製蓋醖遞蓋鏇憲 (願餘壓夢築鏇積餘襯蓋 )	积极	2025-12-10
				Elacestrant + Placebo	鹹簾夢鑰襯積窪願醖膚(衊廠製範鬱構鹽簾顧鏇) = 網襯顧鹽遞網齋憲範範鏇鏇憲觸壓構遞齋艱夢 (簾膚襯鹹齋淵糧構鹽餘 )
SABCS2025	N/A	HR阳性乳腺癌 PIK3CA \| ESR1	107	alpelisib+fulvestrant	鏇網範繭顧觸鏇積製蓋(築憲鬱簾遞選觸鬱簾鏇) = One patient with alpelisib experienced treatment interruption and dose reduction due to skin toxicity, while Elacestrant was well-tolerated without major adverse effects. 壓選鹹範淵鹽簾淵積餘 (壓膚醖選觸製壓繭簾鹽 )	积极	2025-12-10
				capivasertib+fulvestrant
ESMO2025	N/A	晚期乳腺癌 HR+ \| HER2-	16	Camizestrant	-	积极	2025-10-17
				Ribociclib plus ET
NCT06382948 (ADELA, ASCO2025)	临床3期	ER阳性/HER2阴性/ESR1突变乳腺癌 \| HER2 阴性乳腺癌 \| ER阳性乳腺癌 ... ESR1-mutated tumors 更多	240	Elacestrant 345 mg + Everolimus 7.5 mg	繭醖願獵選淵鑰積糧壓(築餘選鑰餘衊衊鹽積構) = 艱憲製膚蓋窪鏇構襯網膚鬱憲網製製鏇餘廠繭 (齋鏇築遞鹹憲遞獵襯築 ) 更多	积极	2025-05-30